Evidence map›Paper›PMID 26961748›Full record

ArticleBMC medical genomics2016

Efficient and biologically relevant consensus strategy for Parkinson's disease gene prioritization.

Maykel Cruz-Monteagudo, Fernanda Borges, Cesar Paz-Y-Miño, M Natália D S Cordeiro, Irene Rebelo, Yunierkis Perez-Castillo, Aliuska Morales Helguera, Aminael Sánchez-Rodríguez, Eduardo Tejera

Open access · goldAbstract read
In one paragraph

Article in BMC medical genomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. NFBTA: A Potent Cytotoxic Agent against Glioblastoma.Molecules (Basel, Switzerland) · 2019
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Maykel Cruz-MonteagudoCIQUP/Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Porto, 4169-007, Portugal. gmailkelcm@yahoo.es.
Fernanda BorgesCIQUP/Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Porto, 4169-007, Portugal. fborges@fc.up.pt.
Cesar Paz-Y-MiñoInstituto de Investigaciones Biomédicas (IIB), Universidad de Las Américas, 170513, Quito, Ecuador. cesar.pazymino@udla.edu.ec.
M Natália D S CordeiroREQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4169-007, Porto, Portugal. ncordeir@fc.up.pt.
Irene RebeloREQUIMTE, Department of Biochemistry, Faculty of Pharmacy, University of Porto, 4050-313, Porto, Portugal. irebelo@ff.up.pt.
Yunierkis Perez-CastilloSección Físico Química y Matemáticas, Departamento de Química, Universidad Técnica Particular de Loja, San Cayetano Alto S/N, EC1101608, Loja, Ecuador. yunierkis@gmail.com.
Aliuska Morales HelgueraMolecular Simulation and Drug Design Group, Centro de Bioactivos Químicos (CBQ), Central University of Las Villas, Santa Clara, 54830, Cuba. aliuska@uclv.edu.cu.
Aminael Sánchez-RodríguezDepartamento de Ciencias Naturales, Universidad Técnica Particular de Loja, Calle París S/N, EC1101608, Loja, Ecuador. asanchez2@utpl.edu.ec.
Eduardo TejeraInstituto de Investigaciones Biomédicas (IIB), Universidad de Las Américas, 170513, Quito, Ecuador. eduardo.tejera@udla.edu.ec.
Universidade do Porto · PTUniversidad de Las Américas · ECUniversidad Técnica Particular de Loja · ECUniversidad Central "Marta Abreu" de las Villas (UCLV) · CU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe systemic information enclosed in microarray data encodes relevant clues to overcome the poorly understood combination of genetic and environmental factors in Parkinson's disease (PD), which represents the major obstacle to understand its pathogenesis and to develop disease-modifying therapeutics. While several gene prioritization approaches have been proposed, none dominate over the rest. Instead, hybrid approaches seem to outperform individual approaches.

methodsA consensus strategy is proposed for PD related gene prioritization from mRNA microarray data based on the combination of three independent prioritization approaches: Limma, machine learning, and weighted gene co-expression networks.

resultsThe consensus strategy outperformed the individual approaches in terms of statistical significance, overall enrichment and early recognition ability. In addition to a significant biological relevance, the set of 50 genes prioritized exhibited an excellent early recognition ability (6 of the top 10 genes are directly associated with PD). 40 % of the prioritized genes were previously associated with PD including well-known PD related genes such as SLC18A2, TH or DRD2. Eight genes (CCNH, DLK1, PCDH8, SLIT1, DLD, PBX1, INSM1, and BMI1) were found to be significantly associated to biological process affected in PD, representing potentially novel PD biomarkers or therapeutic targets. Additionally, several metrics of standard use in chemoinformatics are proposed to evaluate the early recognition ability of gene prioritization tools.

conclusionsThe proposed consensus strategy represents an efficient and biologically relevant approach for gene prioritization tasks providing a valuable decision-making tool for the study of PD pathogenesis and the development of disease-modifying PD therapeutics.

Indexed as

Genetic Predisposition to DiseaseAlgorithmsCase-Control StudiesGene Expression RegulationGene OntologyGene Regulatory NetworksGenetic Association StudiesHumansMachine LearningOligonucleotide Array Sequence AnalysisParkinson DiseaseReproducibility of Results

Identifiers

PMID26961748
PMCPMC4784386
OpenAlexW2295492382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.